Pharma and Biotech Daily: Novo Nordisk's Semaglutide Shows Promise in Alzheimer's Prevention, Roche's Billion Dollar Gene Therapy Deal, Off-Label GLP-1 Use on the Rise

Pharma and BioTech Daily

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. A study has found that Novo Nordisk's semaglutide may reduce the risk of Alzheimer's disease by 40% to 70%. Roche has entered a potential $1 billion gene therapy deal with Dyno Therapeutics, focusing on neurological diseases. Off-label prescribing of GLP-1 receptor agonists for type 1 diabetes has increased, despite lack of FDA approval. Viking Therapeutics plans to accelerate the development of an obesity drug with two Q4 catalysts. Trilink Biotechnologies has expanded its mRNA synthesis services offerings for screening studies. The USP aims to double its volunteer applicant pool, while a CDC panel recommends pneumococcal vaccines for adults aged 50-64. Updates on companies like Catalent, Sangamo, and Moderna are also included in today's news. Additionally, the FDA has approved Pfizer's Abrysvo as the first RSV vaccine for younger adults.